Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial

about

Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial

Item

http://www.wikidata.org/entity/Q37267608

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 September 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Chemotherapy plus Ofatumumab a ...... II randomised controlled trial

@en

Chemotherapy plus Ofatumumab a ...... II randomised controlled trial

@en-gb

Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL

@nl

type

Item

label

Chemotherapy plus Ofatumumab a ...... II randomised controlled trial

@en

Chemotherapy plus Ofatumumab a ...... II randomised controlled trial

@en-gb

Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL

@nl

prefLabel

Chemotherapy plus Ofatumumab a ...... II randomised controlled trial

@en

Chemotherapy plus Ofatumumab a ...... II randomised controlled trial

@en-gb

Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL

@nl

P1154

2-s2.0-84988493287

http://www.w3.org/2001/XMLSchema#string

P1433

Trials

P1476

Chemotherapy plus Ofatumumab a ...... II randomised controlled trial

@en

P2093

Adrian Bloor

http://www.w3.org/2001/XMLSchema#string

Anna Hockaday

http://www.w3.org/2001/XMLSchema#string

David Phillips

http://www.w3.org/2001/XMLSchema#string

Dena R Howard

http://www.w3.org/2001/XMLSchema#string

Jamie B Oughton

http://www.w3.org/2001/XMLSchema#string

Talha Munir

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

A flexible design for multiple armed screening trials.

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia.

The clinical and epidemiological burden of chronic lymphocytic leukaemia.

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.

Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial.

Sample size tables for exact single-stage phase II designs.

A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.

P2888

s13063-016-1581-0

P304

456

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13063-016-1581-0

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-09-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1036728934

http://www.w3.org/2001/XMLSchema#string

P6366

2522898261

http://www.w3.org/2001/XMLSchema#string

P6409

81711996

http://www.w3.org/2001/XMLSchema#string

P698

27645620

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

chemotherapy

P932

5028943

http://www.w3.org/2001/XMLSchema#string

P953

104258/